Merck (MRK)

Merck & Co., Inc. (MRK) announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for use in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.
FDA approval is the first step in an important two-step process. The next step in the process is an Advisory Committee on Immunization Practices vote on whether to recommend administration of GARDASIL for use in males.

Oct 16 · 2:04:00 PM · Source: Business Wire
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter